礼来计划年底前递交efsitora用于治疗2型糖尿病成人患者的上市申请

Core Insights - Eli Lilly plans to submit a marketing application for efsitora, an insulin treatment for adult patients with type 2 diabetes (T2DM), to global regulatory authorities by the end of this year [1] Group 1: Clinical Trial Results - The company announced detailed results from three Phase 3 clinical studies: QWINT-1, QWINT-3, and QWINT-4 [1] - These studies evaluated the efficacy and safety of efsitora alfa administered once weekly compared to daily basal insulin in T2DM adult patients [1] - All studies achieved their primary endpoints, demonstrating that weekly efsitora is non-inferior to daily basal insulin in reducing hemoglobin A1C levels [1]